Clinical Trials on Plasma Cell Leukemia

Total 36031 results

First Affiliated Hospital Xi'an Jiaotong University
Eureka Therapeutics Inc.

Unknown

ET190L1-ARTEMIS™ T Cells in Relapsed, Refractory B Cell Leukemia and Lymphoma

CD19+ Lymphoma, B-Cell | CD19+ Leukemia, B-Cell

China
SWOG Cancer Research Network
National Cancer Institute (NCI)

Active, not recruiting

S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma

DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
Beijing Boren Hospital

Recruiting

Donor-Derived CD5 CAR T (CT125B) Cells for Relapsed or Refractory T- Cell Acute Lymphoblastic Leukemia/Lymphoma

T-Cell Acute Lymphoblastic Leukemia/Lymphoma

China
Abramson Cancer Center of the University of Pennsylvania

Withdrawn

Study of Efficacy and Safety of CTL019 in Adult ALL Patients

B-cell Acute Lymphoblastic Leukemia | Refractory B-cell Acute Lymphoblastic Leukemia | Relapsed B-cell Acute Lymphoblastic Leukemia
National Cancer Institute (NCI)

Completed

Study of Akt Inhibitor MK2206 in Patients With Relapsed Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Mixed Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma | Recurrent Adult Immunoblastic... and other conditions

United States
Memorial Sloan Kettering Cancer Center
Massachusetts General Hospital; BeiGene USA, Inc.; Roche-Genentech

Recruiting

Study of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients With Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL)

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Leukemia (SLL)

United States
German CLL Study Group
Cancer Trials Ireland; Stichting Hemato-Oncologie voor Volwassenen Nederland... and other collaborators

Active, not recruiting

Ibrutinib Monotherapy Versus Fixed-duration Venetoclax Plus Obinutuzumab Versus Fixed-duration Ibrutinib Plus Venetoclax in Patients With Previously Untreated Chronic Lymphocytic Leukaemia (CLL) (CLL17)

Chronic Lymphoid Leukemia

Spain, Ireland, Austria, Denmark, Israel, Norway, Germany, Switzerland, Italy, Belgium, Finland, Sweden, Netherlands
AbbVie

Completed

A Study of the Safety and Efficacy of Venetoclax in Japanese Participants With Relapsed and Refractory Chronic Lymphocytic Leukemia (Including Small Lymphocytic Leukemia) (VENCLL regPMOS)

Cancer | Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Leukemia (SLL)

Japan
National Cancer Institute (NCI)

Recruiting

Phase I Study of Anti-CD22 Chimeric Receptor T Cells in Patients With Relapsed/Refractory Hairy Cell Leukemia and Variant

Hairy Cell Leukemia | Hairy Cell Leukemia Variant

United States
AbbVie
F. Hoffmann-La Roche Ltd; German CLL Study Group (GCLLSG); Dana-Farber Cancer...

Recruiting

Study to Assess Change in Disease Activity and Adverse Events of Oral Venetoclax With Intravenous (IV) Obinutuzumab in Adult Participants With Recurring Chronic Lymphocytic Leukemia (CLL) (ReVenG)

Chronic Lymphocytic Leukemia (CLL)

United States, Australia, Austria, Bulgaria, Germany, Italy, Spain, Israel, Brazil, Romania
AbbVie

Completed

A Study to Assess Effectiveness of Venclexta (Venetoclax) in Patients With Relapse or Refractory Chronic Lymphocytic Leukemia in Routine Clinical Practice in Russian Federation (FORTE)

Cancer | Chronic Lymphocytic Leukemia (CLL)

Russian Federation
MingSight Pharmaceuticals, Inc
Shenzhen MingSight Relin Pharmaceutical Co., Ltd

Recruiting

A Study of MS-553 in Patients With Relapsed or Refractory B-cell Lymphoma

Chronic Lymphocytic Leukemia (CLL) | Small Lymphocytic Lymphoma (SLL) | Mantle Cell Lymphoma (MCL) | Diffuse Large B-cell Lymphoma (DLBCL) | Follicular Lymphoma (FL) | Relapsed or Refractory B-cell Lymphoma | Marginal Zone Lymphoma (MZL)

China
Novartis Pharmaceuticals

Terminated

Study of Oral LBH589 in Patients With Cutaneous T-cell Lymphoma and Adult T-cell Leukemia/Lymphoma

Leukemia-Lymphoma, Adult T-Cell | Cutaneous T-Cell Lymphoma

Japan
Chongqing Precision Biotech Co., Ltd

Recruiting

CD19 and CD22 Targeted CAR-T Cell Therapy for Relapsed/Refractory B Cell Leukemia and Lymphoma

Lymphoma, B-Cell | Leukemia, B-cell

China
University of Erlangen-Nürnberg Medical School
German Research Foundation; University Hospital, Essen; Wuerzburg University... and other collaborators

Unknown

Open-label Clinical Trial to Investigate the Safety and Tolerability of Allogeneic B-cell Concentrates for Immune Reconstitution After Allogeneic Stem Cell Transplantation Measured as Response to a Antedated Single Vaccination (B-cell therapy)

Acute Myeloid Leukemia | Multiple Myeloma | Acute Lymphoblastic Leukemia | Chronic Myeloid Leukemia | Myelodysplastic Syndrome | Aplastic Anemia | Non Hodgkin's Lymphoma | Hodgkin's Disease

Germany
PETHEMA Foundation

Completed

Panobinostat in Combination With Idarubicin and Cytarabine in Patients Aged 65 Years or Older With Newly Diagnosed Acute Myeloblastic Leukaemia (AML) (PANOBIDARA)

Acute Myeloblastic Leukaemia

Spain
medac GmbH

Completed

Treosulfan Based Conditioning Acute Myeloid Leukaemia (AML)

Acute Myeloid Leukaemia

Germany
PETHEMA Foundation

Completed

Treatment of the Acute Myeloblastic Leukaemia in Patients Over 65 Years

Acute Myeloblastic Leukaemia

Spain
AstraZeneca

Completed

Safety, Tolerability and PK of AZD1152 in Patients With Relapsed Acute Myeloid Leukaemia (AML)

Acute Myeloid Leukaemia

Japan
Shenzhen Second People's Hospital

Unknown

CART19 Cells Treatment of MRD of B Cell Malignancies and Then Auto-HSCT

Lymphoma, B-Cell | Leukemia, Lymphocytic, Chronic, B-Cell | Leukemia, Lymphocytic, Acute, B-Cell

China
Chinese PLA General Hospital

Unknown

A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma

B Cell Lymphoma | B Cell Leukemia

China
Masonic Cancer Center, University of Minnesota

Completed

Total Marrow Irradiation for Refractory Acute Leukemia

Multiple Myeloma | Acute Lymphoblastic Leukemia | Myelodysplastic Syndrome

United States
Nanfang Hospital of Southern Medical University

Recruiting

Precision Diagnosis Directing HDACi and TKI Target Therapy for Adult Ph-like ALL

Leukemia | Leukemia, B-cell | Leukemia, Acute | Leukemia, Lymphoblastic

China
University Hospital Heidelberg

Recruiting

Treatment of Patients With Relapsed or Refractory CD19+ Lymphoid Disease With T Cells Expressing a Third-generation CAR

Follicular Lymphoma | Mantle Cell Lymphoma | Chronic Lymphocytic Leukemia | Diffuse Large B Cell Lymphoma | Acute Lymphoblastic Leukemia, Pediatric | Acute Lymphoblastic Leukemia, Adult

Germany
Stemline Therapeutics, Inc.
The Leukemia and Lymphoma Society

Completed

SL-401 in Patients With Blastic Plasmacytoid Dendritic Cell Neoplasm or Acute Myeloid Leukemia

Acute Myeloid Leukemia | Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

United States
Case Comprehensive Cancer Center

Completed

Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies

Chronic Myelomonocytic Leukemia | Recurrent Adult Acute Myeloid Leukemia | Juvenile Myelomonocytic Leukemia | Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Nodal Marginal Zone B-cell Lymphoma | Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell... and other conditions

United States
Kunming Hope of Health Hospital

Withdrawn

Anti-CD19 Universal CAR-NK Cells Therapy Combined With HSCT for B Cell Hematologic Malignancies

B-cell Lymphoma | B-cell Leukemia

China
National Cancer Institute (NCI)

Completed

Bortezomib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Previously Untreated Symptomatic Multiple Myeloma

DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
Fred Hutchinson Cancer Center
National Cancer Institute (NCI)

Completed

Bortezomib and Vorinostat in Treating Patients With Multiple Myeloma Who Have Undergone Autologous Stem Cell Transplant

DS Stage I Plasma Cell Myeloma | DS Stage II Plasma Cell Myeloma | DS Stage III Plasma Cell Myeloma

United States
Shenzhen BinDeBio Ltd.
Xiangya Hospital of Central South University

Recruiting

A Clinical Study of CAR-T Cells Treatment for Children With CD19+/CD22+ R/R ALL and Lymphoma

Relapsed B-cell Acute Lymphoblastic Leukemia, Childhood | Refractory B-cell Acute Lymphoblastic Leukemia, Childhood | Relapsed/Refractory B-cell Lymphoma, Childhood

China
Children's Oncology Group

Active, not recruiting

Palbociclib in Combination With Chemotherapy in Treating Children With Relapsed Acute Lymphoblastic Leukemia (ALL) or Lymphoblastic Lymphoma (LL)

Lymphoblastic Lymphoma | Acute Leukemia | Recurrent Disease | T-cell Lymphoma | Leukemia, Lymphocytic | T-cell Leukemia

United States
Asana BioSciences

Terminated

A Phase 1/2 Study To Evaluate ASN002 In Relapsed/Refractory Lymphoma And Advanced Solid Tumors

Lymphoma, Follicular | Lymphoma, Large B-Cell, Diffuse | Lymphoma, Non-Hodgkin | Cancer | Lymphoma, Malignant | Myelofibrosis | Lymphoma, Mantle-Cell | Chronic Lymphocytic Leukemia | Peripheral T-Cell Lymphoma | Tumor | Neoplasm | B-Cell Chronic Lymphocytic Leukemia | Leukemia, Lymphocytic, Chronic | Idiopathic Myelofibrosis and other conditions

United States, Argentina
University of California, Davis
Novartis

Completed

Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer

Multiple Myeloma | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Adult Hodgkin Lymphoma | Refractory Chronic Lymphocytic Leukemia

United States
Bristol-Myers Squibb

Withdrawn

Study of MDX-1411 in Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma (MDX1411-02)

Chronic Lymphocytic Leukemia or Mantle Cell Lymphoma.
University Hospital, Clermont-Ferrand

Recruiting

Venetoclax Resistance Landscape in Chronic Lymphocytic Leukemia (RAVEN)

Chronic Lymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia | CLL | Relapsed Chronic Lymphocytic Leukemia | Progressive Chronic Lymphocytic Leukemia

France
Leslie Andritsos
Celgene Corporation

Completed

Lenalidomide in Acute Leukemias and Chronic Lymphocytic Leukemia.

Acute Myeloid Leukemia | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia

United States
National Cancer Institute (NCI)

Terminated

Flavopiridol in Treating Patients With Chronic Lymphocytic Leukemia or Prolymphocytic Leukemia

B-cell Chronic Lymphocytic Leukemia | Prolymphocytic Leukemia | Refractory Chronic Lymphocytic Leukemia

United States
M.D. Anderson Cancer Center
National Cancer Institute (NCI); Ziopharm Oncology

Completed

CD19-Specific T-cells in Treating Patients With Advanced Lymphoid Malignancies

Acute Lymphoblastic Leukemia | Non-Hodgkin Lymphoma | Minimal Residual Disease | Small Lymphocytic Lymphoma | Acute Biphenotypic Leukemia | Stage III Chronic Lymphocytic Leukemia | Stage IV Chronic Lymphocytic Leukemia | CD19 Positive | Blasts 5 Percent or More of Bone Marrow Nucleated Cells

United States
Daiichi Sankyo

Active, not recruiting

Valemetostat Tosylate (DS-3201b), an Enhancer of Zeste Homolog (EZH) 1/2 Dual Inhibitor, for Relapsed/Refractory Peripheral T-Cell Lymphoma (VALENTINE-PTCL01)

Relapsed/Refractory Peripheral T-Cell Lymphoma | Adult T Cell Leukemia/Lymphoma

United States, Spain, Japan, United Kingdom, Korea, Republic of, France, Italy, Australia, Canada, Germany, Netherlands, Taiwan
National Cancer Institute (NCI)

Completed

Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma

Recurrent Small Lymphocytic Lymphoma | Refractory Chronic Lymphocytic Leukemia | Recurrent Chronic Lymphocytic Leukemia | Refractory Small Lymphocytic Lymphoma | Recurrent B-Cell Prolymphocytic Leukemia | Refractory B-Cell Prolymphocytic Leukemia

United States
Kyowa Kirin Co., Ltd.

Completed

Phase II Study of KW-0761 in Subjects With CCR4-positive Adult T-cell Leukemia-lymphoma

Adult T-cell Leukemia-lymphoma

Japan
Masonic Cancer Center, University of Minnesota

Withdrawn

T-Regulatory Cell and CD3 Depleted Double Umbilical Cord Blood Transplantation in Hematologic Malignancies

Follicular Lymphoma | Acute Myeloid Leukemia | Lymphoblastic Lymphoma | Chronic Lymphocytic Leukemia | Lymphoplasmacytic Lymphoma | Acute Lymphocytic Leukemia | Mantle-Cell Lymphoma | Hematologic Malignancy | Small Lymphocytic Lymphoma | Burkitt's Lymphoma | Marginal Zone B-cell Lymphoma | Chronic Myeloproliferative... and other conditions

United States
Huazhong University of Science and Technology
Shanghai IASO Biotechnology Co., Ltd

Not yet recruiting

Safety and Efficacy of CT125A Cells for Treatment of Relapsed/Refractory CD5+ Hematopoietic Malignancies

Chronic Lymphocytic Leukemia (CLL) | Peripheral T-cell Lymphomas (PTCL) | CD5+ Relapsed/Refractory Hematopoietic Malignancies | Mantle Cell Lymphoma (MCL) | Diffuse Large B-cell Lymphoma (DLBCL) | Follicular Lymphoma (FL)
Beijing Boren Hospital
Nanjing Legend Biotech Co.

Terminated

LCAR-T2C CAR-T Cells in Relapsed or Refractory CD4+ T Lymphocyte Tumor

T-cell Leukemia | T Cell Lymphoma

China
BeiGene

Recruiting

Study of Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Obinutuzumab in Participants With Chronic Lymphocytic Leukemia (CLL)

CLL

Australia, United States, New Zealand, Korea, Republic of, Canada, Puerto Rico
Sidney Kimmel Comprehensive Cancer Center at Johns...
National Cancer Institute (NCI)

Completed

Donor Bone Marrow Transplantation in Treating Patients With Hematologic Cancer

Myelodysplastic Syndromes | Leukemia | Multiple Myeloma and Plasma Cell Neoplasm

United States
Asan Medical Center

Terminated

Acute Lymphoblastic Leukemia Registry at Asan Medical Center

Lymphoblastic Lymphoma | Leukemia, Biphenotypic, Acute | Leukemia, Acute Lymphoblastic | Leukemia, Lymphoblastic, Acute, Philadelphia-Positive | Precursor B-Cell Lymphoblastic Leukemia

Korea, Republic of
Chongqing Precision Biotech Co., Ltd

Recruiting

CD19+Targeted CAR-T Cell Therapy for Relapsed/Refractory CD19+ B Cell Leukemia and Lymphoma

Lymphoma, B-Cell | Lymphoma, Large B-Cell, Diffuse | Leukemia | Leukemia, Lymphocytic, Chronic, B-Cell | Leukemia, B-cell

China
National Cancer Institute (NCI)

Recruiting

Testing the Addition of an Anti-cancer Drug, Lenalidomide, to the Usual Combination Chemotherapy Treatment ("EPOCH") for Adult T-Cell Leukemia-Lymphoma (ATL)

Acute Adult T-Cell Leukemia/Lymphoma | Adult T-Cell Leukemia/Lymphoma | Chronic Adult T-Cell Leukemia/Lymphoma | HTLV-1 Infection

United States
Genentech, Inc.

Completed

A Study of GDC-0853 in Patients With Resistant B-Cell Lymphoma or Chronic Lymphocytic Leukemia.

Lymphocytic Leukemia, Chronic, Diffuse Large B-Cell Lymphoma

United States, Australia

Clinical Trials on Plasma Cell Leukemia

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Cameroon

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations